1/16
05:17 am
agen
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal [Yahoo! Finance]
High
Report
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal [Yahoo! Finance]
1/15
08:43 am
agen
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. [Yahoo! Finance]
High
Report
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. [Yahoo! Finance]
1/15
08:30 am
agen
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
High
Report
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
1/15
07:01 am
agen
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
High
Report
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
1/12
07:30 am
agen
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Medium
Report
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
1/5
06:41 pm
agen
Agenus (AGEN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Agenus (AGEN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
1/5
05:01 pm
agen
Agenus (AGEN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Agenus (AGEN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
12/30
04:09 pm
agen
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
08:05 am
agen
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Low
Report
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
12/4
01:48 am
agen
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript [Seeking Alpha]
11/26
02:01 pm
agen
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
04:34 pm
agen
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL [Yahoo! Finance]
Low
Report
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL [Yahoo! Finance]
11/19
04:01 pm
agen
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Low
Report
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
11/18
08:53 am
agen
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC [Yahoo! Finance]
Low
Report
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC [Yahoo! Finance]
11/18
08:41 am
agen
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
Low
Report
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
11/14
01:10 pm
agen
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
07:41 am
agen
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances [Yahoo! Finance]
Medium
Report
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances [Yahoo! Finance]
11/10
07:30 am
agen
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Medium
Report
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
11/5
01:47 pm
agen
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Low
Report
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
10/20
08:21 am
agen
Agenus (NASDAQ:AGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Agenus (NASDAQ:AGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright.